gst glutathione s-transferases Glutathione-S-Transferases as Potential Targets for Modulation of Nitric Oxide-Mediated Vasodilation Enhanced soluble expression of glutathione
Description
24 weeks (full ladder to 15 mg) 6 x 40 mg vials Add buffer for any held-dose weeks during GI flares
MultiSciences, F41011b04, F21480A02
Mechanistically, the triple-agonist design is a deliberate departure from the GLP-1-monoagonist (liraglutide, semaglutide) and GIP/GLP-1-dual-agonist (tirzepatide) classes
Different mechanisms, no overlap, and they seem to amplify each other's effects
